On June 30, 2023, LEXICON PHARMACEUTICALS ($NASDAQ:LXRX) reported its financial results for the second quarter of fiscal year 2023, with total revenue amounting to USD 0.3 million – an increase from the 0.0 million reported in the same quarter of the prior year. Net income for the quarter was -44.9 million, down from the -24.6 million reported last year.
The company’s stock opened at $1.9 and closed at $1.9, increasing by 1.6% from its previous closing price of $1.9. This increase in stock price was an indication of investor confidence in the company’s financial performance. The company reported strong overall financial results in the second quarter of the fiscal year. This suggests that Lexicon Pharmaceuticals is on track to meet or exceed its financial goals for the year.
Overall, Lexicon Pharmaceuticals reported strong performance in the second quarter of FY2023. Investors remain optimistic about the company’s future prospects and are encouraged by the increasing stock price, which reflects the company’s solid financial performance. With a strong financial outlook in place, Lexicon Pharmaceuticals is poised for even greater success in the near future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Lexicon Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lexicon Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lexicon Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Lexicon Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Lexicon Pharmaceuticals Intrinsic Stock Value
At GoodWhale, we strive to give our customers the best possible insight into the wellbeing of the stocks they are holding. As part of this, we recently conducted a comprehensive analysis of LEXICON PHARMACEUTICALS. After reviewing the data, our proprietary Valuation Line calculated that the fair value of their share is around $2.8. Currently, LEXICON PHARMACEUTICALS stock is being traded at $1.9, representing an undervaluation of 32.1%. This means that investors can purchase these shares at a discount and potentially benefit from a significant return in the future. More…
Risk Rating Analysis
Star Chart Analysis
The pharmaceutical industry is fiercely competitive, with companies constantly vying for market share. This is especially true in the case of Lexicon Pharmaceuticals Inc, which faces stiff competition from Calithera Biosciences Inc, Shanghai Allist Pharmaceuticals Co Ltd, and Incyte Corp.
– Calithera Biosciences Inc ($NASDAQ:CALA)
Calithera Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for the treatment of cancer. The company’s market cap as of 2022 is 12.7M. The company’s ROE for the same year is -212.85%. The company’s focus on the development and commercialization of small molecule drugs for the treatment of cancer makes it a unique player in the biopharmaceutical industry.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 10.34B as of 2022. The company’s return on equity is -1.27%. Shanghai Allist Pharmaceuticals Co Ltd is engaged in the research and development, manufacture and sale of pharmaceutical products.
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of 2022, Incyte has a market capitalization of $17.25 billion and a return on equity of 9.94%. The company’s primary focus is on the development of drugs for the treatment of cancer. Incyte’s most popular drug, Jakafi (ruxolitinib), is approved for the treatment of several types of blood cancers. Incyte is also investigating other potential uses for Jakafi, including the treatment of solid tumors.
Investors interested in Lexicon Pharmaceuticals should consider the company’s financial performance for the second quarter of FY2023. Revenue for the quarter saw a modest increase over the previous year, coming in at USD 0.3 million. However, net income for the quarter was -44.9 million, a significant decrease from -24.6 million in the same quarter of the previous year. While this is a concerning downward trend, investors should pay attention to any potential developments that might improve Lexicon’s bottom line and watch for any signs of a potential turnaround.